RCAR Stock Overview
A development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RenovaCare, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.30 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RCAR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | 0% | 18.8% | 32.3% |
Return vs Industry: RCAR underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: RCAR underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| RCAR volatility | |
|---|---|
| RCAR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RCAR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RCAR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | n/a | Harmel Rayat | www.renovacareinc.com |
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs.
RenovaCare, Inc. Fundamentals Summary
| RCAR fundamental statistics | |
|---|---|
| Market cap | US$87.00 |
| Earnings (TTM) | -US$5.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs RCAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCAR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.74m |
| Earnings | -US$5.74m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RCAR perform over the long term?
See historical performance and comparison